Rinvoq®

INN: upadacitinib

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Oral Small Molecule (JAK inhibitor)

Delivery Route

Oral (tablet)

Health Canada Approval

2019

Storage

Store at 2 to 25°C in original bottle with the desiccant inside to protect from moisture.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

Can cause fetal harm; women of reproductive potential should be advised to use contraception during treatment and for at least 4 weeks following the final dose.

Breastfeeding Indication

Not recommended.

Pediatric Indication

The safety and efficacy of Rinvoq® in children and adolescents aged 0 to <18 years with ulcerative colitis or Crohn’s disease have not yet been established.

Learn More

View the Rinvoq® product monograph.